FR09C0011I2 - - Google Patents

Info

Publication number
FR09C0011I2
FR09C0011I2 FR09C0011C FR09C0011C FR09C0011I2 FR 09C0011 I2 FR09C0011 I2 FR 09C0011I2 FR 09C0011 C FR09C0011 C FR 09C0011C FR 09C0011 C FR09C0011 C FR 09C0011C FR 09C0011 I2 FR09C0011 I2 FR 09C0011I2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR09C0011C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26736901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR09C0011(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of FR09C0011I1 publication Critical patent/FR09C0011I1/fr
Application granted granted Critical
Publication of FR09C0011I2 publication Critical patent/FR09C0011I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR09C0011C 1997-08-28 2009-03-12 Active FR09C0011I2 (pm)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5780397P 1997-08-28 1997-08-28
US6983797P 1997-08-28 1997-08-28
PCT/EP1998/005414 WO1999011605A1 (en) 1997-08-28 1998-08-26 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives

Publications (2)

Publication Number Publication Date
FR09C0011I1 FR09C0011I1 (pm) 2009-04-17
FR09C0011I2 true FR09C0011I2 (pm) 2011-04-01

Family

ID=26736901

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0011C Active FR09C0011I2 (pm) 1997-08-28 2009-03-12

Country Status (34)

Country Link
US (5) US6291523B1 (pm)
EP (1) EP1007505B1 (pm)
JP (1) JP3704470B2 (pm)
KR (1) KR100637296B1 (pm)
CN (1) CN1140500C (pm)
AR (1) AR015157A1 (pm)
AT (1) ATE237580T1 (pm)
AU (1) AU743371B2 (pm)
BR (1) BR9812010B1 (pm)
CA (1) CA2298033C (pm)
CO (1) CO4960662A1 (pm)
CY (1) CY2007020I1 (pm)
CZ (1) CZ298522B6 (pm)
DE (4) DE122007000035I1 (pm)
DK (1) DK1007505T3 (pm)
ES (1) ES2197508T3 (pm)
FR (1) FR09C0011I2 (pm)
HU (1) HU225774B1 (pm)
ID (1) ID23953A (pm)
IL (2) IL134498A0 (pm)
LU (2) LU91346I2 (pm)
MY (1) MY127881A (pm)
NL (1) NL300379I2 (pm)
NO (2) NO326196B1 (pm)
NZ (1) NZ502669A (pm)
PE (1) PE108099A1 (pm)
PL (1) PL194480B1 (pm)
PT (1) PT1007505E (pm)
RU (1) RU2186762C2 (pm)
SI (1) SI1007505T1 (pm)
SK (1) SK283773B6 (pm)
TR (1) TR200000447T2 (pm)
TW (1) TWI250142B (pm)
WO (1) WO1999011605A1 (pm)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
EP1126841B1 (en) * 1998-11-02 2004-12-15 Merck & Co., Inc. Combinations of a 5ht1b/1d agonist and a selective cox-2 inhibitor for the treatment of migraine
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
GB9922830D0 (en) * 1999-09-27 1999-11-24 Novartis Ag Processes
JP2003523954A (ja) 1999-12-08 2003-08-12 ファルマシア コーポレイション 治療効果が迅速に開始されるシクロオキシゲナーゼ−２阻害剤組成物
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
AU2001216038A1 (en) * 2000-11-14 2002-05-27 Alcon Laboratories Inc. Treatment of glaucoma and ocular hypertension
US20050264906A1 (en) * 2004-05-25 2005-12-01 Haratsch Erich F Method and apparatus for reduced-state Viterbi detection in a read channel of a magnetic recording system
US7656959B2 (en) 2001-04-13 2010-02-02 Agere Systems Inc. Pipelined decision-feedback unit in a reduced-state viterbi detector with local feedback
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
BR0212435A (pt) 2001-09-10 2004-08-17 Sugen Inc Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase
US7288246B2 (en) 2001-09-13 2007-10-30 The Board Of Regents Of The University Of Oklahoma Method of alleviating chronic pain via peripheral glutaminase regulation
US7504231B2 (en) * 2001-09-13 2009-03-17 The Board Of Regents Of The University Of Oklahoma Method of alleviating chronic pain via peripheral inhibition of neurotransmitter synthesis
GB0124459D0 (en) * 2001-10-11 2001-12-05 Novartis Ag Organic compounds
NZ532418A (en) * 2001-10-25 2007-02-23 Novartis Ag Combinations comprising a selective cyclooxygenase-2 inhibitor and a microtubule interfering agent
CA2461373A1 (en) * 2001-11-06 2003-05-15 Novartis Ag Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
RU2318497C2 (ru) * 2002-03-07 2008-03-10 Новартис Аг Фармацевтические композиции
GB0209257D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
CA2487414A1 (en) 2002-06-11 2003-12-18 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
ITMI20021391A1 (it) 2002-06-25 2003-12-29 Nicox Sa Nitroderivati di inibitori della cicloossigenasi-2
US20060115500A1 (en) 2002-07-23 2006-06-01 Jithan Aukunuru Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
WO2004028448A2 (en) * 2002-09-13 2004-04-08 Miller Kenneth E Method of alleviating pain via inhibition of neurotransmitter synthesis
GB0224198D0 (en) * 2002-10-17 2002-11-27 Novartis Ag Organic compounds
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
AR042206A1 (es) 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
EP1575581A1 (en) * 2002-12-18 2005-09-21 Novartis AG Combinations of valsartan with cox-2 inhibitors
US7157577B2 (en) 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
TWI327913B (en) * 2003-03-12 2010-08-01 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
WO2004093816A2 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent
US20040220187A1 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
US20060135506A1 (en) * 2003-04-22 2006-06-22 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
WO2004093895A1 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
DK1534305T3 (da) 2003-05-07 2007-02-05 Osteologix As Behandling af brusk-/knoglelidelser med vandoplöselige strontiumsalte
US20050107387A1 (en) * 2003-05-13 2005-05-19 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
WO2004103286A2 (en) * 2003-05-14 2004-12-02 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cholimergic agent
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
WO2004105699A2 (en) * 2003-05-28 2004-12-09 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
WO2005007106A2 (en) * 2003-07-10 2005-01-27 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a non-nmda glutamate modulator for the treatment of central nervous system damage
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
WO2005009354A2 (en) * 2003-07-17 2005-02-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an ikk inhibitor for the treatment of ischemic-mediated central nervous system disorders or injury
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
WO2005018563A2 (en) * 2003-08-22 2005-03-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
US20050113409A1 (en) * 2003-09-03 2005-05-26 Pharmacia Corporation Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
BRPI0414956A (pt) * 2003-10-03 2006-11-14 Pharmacia Corp composições de um inibidor seletivo da ciclooxigenase-2 administradas sob condições hipotérmicas para o tratamento de distúrbios ou lesões do sistema nervoso central mediados por isquemia
CN1897929A (zh) * 2003-10-08 2007-01-17 诺瓦提斯公司 包含5－甲基－2－(2′－氯－6′－氟苯胺基)苯乙酸的药物组合物
CA2545731A1 (en) * 2003-11-12 2005-05-26 Pharmacia & Upjohn Company Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system mediated disorders
EP2497785B1 (en) 2004-01-07 2018-09-12 Seikagaku Corporation Hyaluronic acid derivative and drug containing the same
US8182792B2 (en) 2004-03-23 2012-05-22 Novartis Ag Pharmaceutical compositions
TW200603792A (en) * 2004-04-23 2006-02-01 Pharmacia & Upjohn Co Llc Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
US7487432B2 (en) * 2004-05-25 2009-02-03 Agere Systems Inc. Method and apparatus for multiple step Viterbi detection with local feedback
US7653154B2 (en) * 2004-05-25 2010-01-26 Agere Systems Inc. Method and apparatus for precomputation and pipelined selection of intersymbol interference estimates in a reduced-state Viterbi detector
US7380199B2 (en) * 2004-05-25 2008-05-27 Agere Systems Inc. Method and apparatus for precomputation and pipelined selection of branch metrics in a reduced-state Viterbi detector
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0416508D0 (en) * 2004-07-23 2004-08-25 Merck Sharp & Dohme Therapeutic agents
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
DE102004044827A1 (de) * 2004-09-16 2006-03-23 Bayer Cropscience Ag Jod-phenylsubstituierte cyclische Ketoenole
DK1817282T3 (da) 2004-11-23 2011-10-10 Astrazeneca Ab Til behandling af respiratoriske sygdomme egnede phenoxy derivater
ATE424386T1 (de) 2004-12-23 2009-03-15 Glaxo Group Ltd Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
BRPI0607801A2 (pt) * 2005-02-22 2009-06-13 Merial Ltd método para tratar seletivamente distúrbio mediado pela cox-2 através da administração de gama-tocoferol
KR100990027B1 (ko) 2005-04-26 2010-10-26 화이자 인코포레이티드 Ｐ-카드헤린 항체
AU2006244393B2 (en) * 2005-05-05 2012-06-21 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
TWI370137B (en) 2005-09-07 2012-08-11 Amgen Fremont Inc Human monoclonal antibodies to activin receptor-like kinase-1
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007039736A1 (en) 2005-10-06 2007-04-12 Astrazeneca Ab Novel compounds
JP2007275193A (ja) * 2006-04-04 2007-10-25 Fujifilm Corp 光プローブおよび光断層画像化装置
AR061623A1 (es) * 2006-06-26 2008-09-10 Novartis Ag Derivados de acido fenilacetico
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
US7943658B2 (en) * 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
US8765815B2 (en) * 2007-09-20 2014-07-01 Ramot At Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
US20090082452A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lumiracoxib
AU2009210446C1 (en) 2008-02-01 2013-01-10 Brickell Biotech, Inc. N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
US8242145B2 (en) 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
US8497381B2 (en) 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
WO2009145989A2 (en) 2008-04-02 2009-12-03 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
UY31956A (es) 2008-07-03 2010-01-29 Amira Pharmaceuticals Inc Antagonistas de heteroalquilo de receptores de prostaglandina d2
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
US8227451B2 (en) * 2008-11-12 2012-07-24 Auspex Pharmaceuticals Phenylacetic acid inhibitors of cyclooxygenase
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
WO2011012622A1 (en) 2009-07-30 2011-02-03 Glaxo Group Limited Benzoxazinone derivatives for the treatment of glytl mediated disorders
CN102596199A (zh) 2009-07-31 2012-07-18 潘米拉制药公司 Dp2受体拮抗剂的眼用医药组合物
CA2768587A1 (en) 2009-08-05 2011-02-10 Panmira Pharmaceuticals, Llc Dp2 antagonist and uses thereof
WO2011023753A1 (en) 2009-08-27 2011-03-03 Glaxo Group Limited Benzoxazine derivatives as glycine transport inhibitors
EP2521713A4 (en) * 2010-01-06 2013-10-02 Panmira Pharmaceuticals Llc ANTAGONIST OF DP2 AND ITS USES
GB201000685D0 (en) 2010-01-15 2010-03-03 Glaxo Group Ltd Novel compounds
GB201007789D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel Compound
GB201007791D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel compounds
ES2529233T3 (es) 2010-07-09 2015-02-18 Convergence Pharmaceuticals Limited Compuestos tetrazol como bloqueadores de canales de calcio
RU2439053C1 (ru) * 2010-08-03 2012-01-10 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" Диариламины и способ их получения
US8892989B1 (en) * 2010-08-26 2014-11-18 Clearslide, Inc. Method for searching companies and people
US8900798B2 (en) 2010-10-18 2014-12-02 Eastman Kodak Company On-press developable lithographic printing plate precursors
US20120090486A1 (en) 2010-10-18 2012-04-19 Celin Savariar-Hauck Lithographic printing plate precursors and methods of use
US20120141941A1 (en) 2010-12-03 2012-06-07 Mathias Jarek Developing lithographic printing plate precursors in simple manner
US20120141935A1 (en) 2010-12-03 2012-06-07 Bernd Strehmel Developer and its use to prepare lithographic printing plates
US20120141942A1 (en) 2010-12-03 2012-06-07 Domenico Balbinot Method of preparing lithographic printing plates
JP6058556B2 (ja) 2011-01-19 2017-01-11 クオンベルゲンセ プハルマセウトイカルス リミテッド ＣａＶ２．２カルシウムチャンネルブロッカーとしてのピペラジン誘導体
US20120199028A1 (en) 2011-02-08 2012-08-09 Mathias Jarek Preparing lithographic printing plates
PE20142083A1 (es) 2011-09-16 2014-12-30 Fovea Pharmaceuticals Derivados de anilina, su preparacion y su aplicacion terapeutica
US8632941B2 (en) 2011-09-22 2014-01-21 Eastman Kodak Company Negative-working lithographic printing plate precursors with IR dyes
US9029063B2 (en) 2011-09-22 2015-05-12 Eastman Kodak Company Negative-working lithographic printing plate precursors
CN102311355B (zh) * 2011-09-26 2014-02-05 扬州天和药业有限公司 罗本考昔的一种制备方法
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
US8679726B2 (en) 2012-05-29 2014-03-25 Eastman Kodak Company Negative-working lithographic printing plate precursors
US9063423B2 (en) 2013-02-28 2015-06-23 Eastman Kodak Company Lithographic printing plate precursors and use
US9201302B2 (en) 2013-10-03 2015-12-01 Eastman Kodak Company Negative-working lithographic printing plate precursor
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
KR102557900B1 (ko) 2016-09-07 2023-07-19 트러스티즈 오브 터프츠 칼리지 면역-dash 억제제와 pge2 길항제를 이용한 병행 요법
WO2018168921A1 (ja) 2017-03-14 2018-09-20 生化学工業株式会社 関節疾患処置用組成物およびこれを含むキット
KR20230173746A (ko) 2017-03-14 2023-12-27 세이가가쿠 고교 가부시키가이샤 관절 질환 처치용 조성물 및 그것을 포함하는 키트
KR102069205B1 (ko) * 2017-08-09 2020-01-22 연성정밀화학(주) 라타노프로스틴 부노드의 제조 방법 및 그를 위한 중간체
CN109694330B (zh) * 2017-10-24 2023-10-20 乳源瑶族自治县东阳光生物科技有限公司 一种酸的制备方法
EA202190330A1 (ru) 2018-07-27 2021-06-04 КРКА, д.д., НОВО МЕСТО Способ получения полиморфной формы робенакоксиба
CN109503399B (zh) * 2018-12-29 2021-12-24 江苏天和制药有限公司 一种罗本考昔的制备方法
CN110437090A (zh) * 2019-07-31 2019-11-12 江苏天和制药有限公司 一种罗本考昔三聚体及其制备方法
CN111807978B (zh) * 2020-07-29 2023-03-14 武汉川泰科技有限公司 一种罗贝考昔的制备方法
US20240165148A1 (en) 2021-03-15 2024-05-23 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
US20250214927A1 (en) 2022-03-23 2025-07-03 Alivira Animal Health Limited An improved process for purification of robenacoxib
CN120004366B (zh) * 2025-04-18 2025-07-25 浙江九安检测科技有限公司 一种二噁英前处理过程中有机试剂的回收方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895063A (en) 1965-04-08 1975-07-15 Ciba Geigy Corp Substituted Anilino Benzyl Alcohols
US3558690A (en) 1965-04-08 1971-01-26 Gelgy Chemical Corp Substituted derivatives of 2-anilinophenylacetic acids and a process of preparation
GB1166861A (en) 1966-01-15 1969-10-15 Aspro Nicholas Ltd New Diphenylamine Derivatives and Compositions containing them
US3652762A (en) 1970-04-14 1972-03-28 Ciba Geigy Corp Pharmaceutical compositions and methods employing substituted derivatives of 2-anilinophenylacetic acids and esters
US4173577A (en) 1970-09-09 1979-11-06 Ciba-Geigy Corporation Phenylacetohydroxamic acids
ES8404783A1 (es) 1983-03-21 1984-05-16 Prodes Sa Procedimiento para la obtencion del ester del acido 2-(2,6-diclorofenil)amino bencenoacetico con acido glicolico.
DE3445011A1 (de) 1983-12-13 1985-06-13 Ciba-Geigy Ag, Basel Neues anilinderivat, verfahren zu seiner herstellung und seine verwendung
GR900100380A (el) * 1989-05-20 1991-10-10 Fisons Plc Μέ?οδος παρασκευής αντι-φλεγμονωδών παραγώγων αμινοφενόλης.
IT1256345B (it) 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
DK0767777T3 (da) 1994-06-29 1999-10-25 Novartis Erfind Verwalt Gmbh Salte af 2-[(2,6-dichlorphenyl)amin]phenylacetoxyeddikesyre med organiske basiske kationer
JPH0977664A (ja) * 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados

Also Published As

Publication number Publication date
WO1999011605A8 (en) 2000-03-02
NL300379I2 (nl) 2010-02-01
JP3704470B2 (ja) 2005-10-12
DE122009000013I1 (de) 2009-06-25
SK283773B6 (sk) 2004-01-08
CA2298033C (en) 2007-10-02
KR20010023344A (ko) 2001-03-26
ATE237580T1 (de) 2003-05-15
NO20000943D0 (no) 2000-02-25
HU225774B1 (en) 2007-08-28
CN1140500C (zh) 2004-03-03
NO326196B1 (no) 2008-10-13
HUP0002514A2 (hu) 2000-12-28
WO1999011605A1 (en) 1999-03-11
DE69813570D1 (de) 2003-05-22
SK2472000A3 (en) 2000-09-12
US6451858B2 (en) 2002-09-17
CY2007020I2 (el) 2012-01-25
ID23953A (id) 2000-06-08
US6727281B2 (en) 2004-04-27
BR9812010B1 (pt) 2010-12-14
PL194480B1 (pl) 2007-06-29
US6310099B1 (en) 2001-10-30
US20020013369A1 (en) 2002-01-31
EP1007505B1 (en) 2003-04-16
KR100637296B1 (ko) 2006-10-23
ES2197508T3 (es) 2004-01-01
US20040122254A1 (en) 2004-06-24
PT1007505E (pt) 2003-08-29
LU91346I2 (fr) 2007-09-11
TR200000447T2 (tr) 2000-07-21
NO2009007I1 (no) 2009-04-06
NO20000943L (no) 2000-02-25
DK1007505T3 (da) 2003-07-21
US7115662B2 (en) 2006-10-03
NO2009007I2 (no) 2010-06-07
CO4960662A1 (es) 2000-09-25
CZ2000714A3 (cs) 2000-06-14
MY127881A (en) 2006-12-29
CA2298033A1 (en) 1999-03-11
TWI250142B (en) 2006-03-01
CN1268112A (zh) 2000-09-27
AU743371B2 (en) 2002-01-24
JP2001514244A (ja) 2001-09-11
AR015157A1 (es) 2001-04-18
BR9812010A (pt) 2000-12-12
DE122007000035I1 (de) 2007-07-19
NZ502669A (en) 2002-02-01
AU9534098A (en) 1999-03-22
IL134498A (en) 2009-06-15
US6291523B1 (en) 2001-09-18
DE122007000035I2 (de) 2010-07-01
HUP0002514A3 (en) 2002-11-28
RU2186762C2 (ru) 2002-08-10
IL134498A0 (en) 2001-04-30
LU91540I2 (fr) 2009-05-11
PE108099A1 (es) 1999-11-18
PL338357A1 (en) 2000-10-23
CY2007020I1 (el) 2012-01-25
EP1007505A1 (en) 2000-06-14
NL300379I1 (nl) 2009-05-06
HK1031374A1 (en) 2001-06-15
US20020183391A1 (en) 2002-12-05
FR09C0011I1 (pm) 2009-04-17
CZ298522B6 (cs) 2007-10-24
DE69813570T2 (de) 2004-02-12
SI1007505T1 (en) 2003-10-31

Similar Documents

Publication Publication Date Title
BE2018C032I2 (pm)
FR09C0011I2 (pm)
CH0944937H2 (pm)
ITMI971410A0 (pm)
IN183753B (pm)
BR9701757A (pm)
IN183096B (pm)
BR9700653A (pm)
IN188739B (pm)
IN189099B (pm)
ITBZ970039A0 (pm)
ITMI970510V0 (pm)
ITRM970301A0 (pm)
ITRM970103V0 (pm)
ITRM970287A0 (pm)
ITVR970031A0 (pm)
CN3055123S (pm)
CN3055519S (pm)
CN3053852S (pm)
CN3053525S (pm)
CN3054162S (pm)
CN3053524S (pm)
CN3053500S (pm)
CN3054556S (pm)
CN3053170S (pm)